BZE-2204

N/A

Report date: 2024/12/23 11:59:13

Base Information

Drug NameBZE-2204
Drug Alias NameBZE2204BZE-2204
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsCD22 modulatorsB-cell maturation protein modulators +[4] 
TargetsB-lymphocyte antigen CD19CD22B-cell maturation protein
Therapy Area/IndicationsLupus Erythematosus, SystemicPurpura, Thrombocytopenic, IdiopathicMyositis +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Cell Therapy Group Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Cell Therapy Group Co Ltd
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, SystemicPurpura, Thrombocytopenic, IdiopathicMyositis +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A